Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: Consistency is the key - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Sun Pharma: Consistency is the key

May 18, 2007

Performance summary
Sun Pharma has reported a strong set of numbers for the fourth quarter and full year ended March 2007. For both the periods under review, the topline has grown at a robust pace, led by both its domestic and export formulations businesses. Operating margins have expanded due to a sharp fall in raw material costs (as percentage of sales) and this impact has been more pronounced in the fourth quarter. All these factors put together, along with the higher other income, have resulted in the bottomline growing at a healthy double-digit pace for both the periods under review.

Consolidated snapshot
(Rs m) 4QFY06 4QFY07 Change FY06 FY07 Change
Net sales 4,067 5,442 33.8% 16,368 21,321 30.3%
Expenditure 3,159 3,897 23.4% 11,454 14,523 26.8%
Operating profit (EBIDTA) 909 1,545 70.0% 4,914 6,798 38.3%
Operating profit margin (%) 22.3% 28.4%   30.0% 31.9%  
Other income 754 942 24.9% 1,665 2,253 35.3%
Depreciation 184 201 9.0% 610 818 34.0%
Profit before tax 1,478 2,286 54.7% 5,969 8,233 37.9%
Tax 113 (18)   239 (67)  
Minority interest (65) 183   (3) 559  
Profit after tax/ (loss) 1,429 2,121 48.4% 5,733 7,741 35.0%
Net profit margin (%) 35.1% 39.0%   35.0% 36.3%  
No. of shares (m) 190.1 193.4   190.1 193.4  
Diluted earnings per share (Rs)*         40.0  
P/E ratio (x)*         25.4  
(* on a trailing 12-month basis)

What to expect?
At the current price of Rs 1,015, the stock is trading at a multiple of 22.1 times our estimated FY09 earnings. We shall soon put up a detailed analysis of the results.

To Read the Full Story, Subscribe or Sign In
To Read the Full Story, Subscribe or Sign In

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


Feb 19, 2019 (Close)


  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks